15 completed, 12 active not recruiting, 10 recruiting, 5 terminated. 47 Phase 1, 17 Phase 2.
Follow Refractory Malignant Solid Neoplasm: new trials by email Literature Review of Refractory Malignant Solid Neoplasm trials Research Report on Refractory Malignant Solid Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1 | Recruiting | Mayo Clinic | 42 | 2025-11-07 | 2026-09-24 |
| Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Melanoma | Phase 1 | Recruiting | Anusha Kalbasi | 18 | 2025-10-07 | 2026-03-17 |
| Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma Bcl-XL Proteolysis Targeting Chimera DT2216, Biospecimen Collection, Irinotecan - Childhood Fibrolamellar Carcinoma, Recurrent Childhood Fibrolamellar Carcinoma | Phase 1 / Phase 2 | Suspended | Children's Oncology Group | 81 | 2025-06-12 | 2026-08-24 |
| Studying TAK-243 in Patients With Advanced Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 95 | 2025-03-24 | 2026-10-13 |
| Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors Axatilimab, Biopsy, Biospecimen Collection - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 / Phase 2 | Recruiting | OHSU Knight Cancer Institute | 38 | 2024-05-21 | 2026-07-08 |
| AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Cholangiocarcinoma, Advanced Hepatocellular Carcinoma | Phase 1 | Suspended | University of Southern California | 36 | 2023-03-29 | 2026-08-17 |
| Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Atezolizumab, Biospecimen Collection, Computed Tomography - Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 86 | 2022-11-17 | 2026-11-12 |
| Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors BET Bromodomain Inhibitor ZEN-3694, Computed Tomography, Core Biopsy - Advanced Malignant Solid Neoplasm, Locally Advanced Pancreatic Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 49 | 2022-11-16 | 2026-11-12 |
| AOH1996 for the Treatment of Refractory Solid Tumors PCNA Inhibitor AOH1996 - Refractory Malignant Solid Neoplasm, Osteosarcoma | Phase 1 | Recruiting | City of Hope Medical Center | 92 | 2022-09-08 | 2026-10-20 |
| Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer BET Bromodomain Inhibitor ZEN-3694, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 42 | 2022-08-02 | 2026-11-12 |
| Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors Cabozantinib, Pamiparib - Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 44 | 2022-02-09 | 2026-05-12 |
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy - Diffuse Midline Glioma, H3 K27-Altered, Metastatic Malignant Neoplasm in the Central Nervous System | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 63 | 2022-01-28 | 2026-09-11 |
| Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors Elimusertib - Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 31 | 2021-12-22 | 2026-01-23 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint - Colorectal Carcinoma, Endometrial Carcinoma | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 147 | 2021-11-08 | 2026-08-25 |
| Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors anti-MESO CAR T cells - Refractory Malignant Solid Neoplasm | Phase 1 | Unknown | Ruijin Hospital | 12 | 2021-10-01 | 2021-09-17 |
| Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma Onivyde, Talazoparib, Temozolomide - Recurrent Solid Tumor, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 90 | 2021-06-09 | 2026-05-19 |
| Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study Biospecimen Collection, Ipilimumab, Nivolumab - Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2021-05-11 | 2026-06-10 | |
| Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas Entinostat, Molibresib - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2020-09-18 | 2020-09-28 | |
| Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 62 | 2020-09-01 | 2026-02-27 |
| Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study Adavosertib, Olaparib - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2020-06-30 | 2026-09-30 |
Showing 20 of 47. Sign in to see all of them.
Neoplasm Metastasis (15) · Central Nervous System Neoplasms (8) · Lymphoma (7) · Melanoma (7) · Pancreatic Neoplasms (7) · Neuroblastoma (6) · Osteosarcoma (5) · Ovarian Neoplasms (5) · Lymphoma, Non-Hodgkin (3) · Prostatic Neoplasms (3) · Rhabdomyosarcoma (3) · Sarcoma (3) · Sarcoma, Ewing (3) · Thyroid Neoplasms (3) · Adenoma, Islet Cell (2)
Neoplasms (41) · Neoplasms by Site (30) · Neoplasms by Histologic Type (24) · Neoplasms, Germ Cell and Embryonal (15) · Neoplasms, Glandular and Epithelial (15) · Neoplastic Processes (15) · Pathologic Processes (15) · Pathological Conditions, Signs and Symptoms (15) · Neoplasms, Nerve Tissue (14) · Neuroectodermal Tumors (14) · Endocrine System Diseases (13) · Digestive System Diseases (12) · Digestive System Neoplasms (12) · Endocrine Gland Neoplasms (12) · Hemic and Lymphatic Diseases (11)
Specimen Handling (15) · Magnetic Resonance Spectroscopy (9) · Biopsy (7) · Irinotecan (5) · Paclitaxel (4) · Taxes (4) · CTLA-4 Antigen (3) · Ipilimumab (3) · Nivolumab (3) · Temozolomide (3) · cabozantinib (3) · entinostat (3) · trametinib (3) · Carboplatin (2) · Cyclophosphamide (2)
National Cancer Institute (NCI) (20) · Children's Oncology Group (9) · M.D. Anderson Cancer Center (8) · Mayo Clinic (2) · OHSU Knight Cancer Institute (2) · University of Southern California (2) · Anusha Kalbasi (1) · City of Hope Medical Center (1) · Ruijin Hospital (1) · St. Jude Children's Research Hospital (1)
United States (45) · Canada (8) · Australia (2) · China (1)
Siqing Fu (3) · Aung Naing (2) · Michael V Ortiz (2) · Patricia M LoRusso (2) · Sarina A Piha-Paul (2) · Timothy A Yap (2) · Allison Betof Warner, MD, PhD (1) · Aminah Jatoi, M.D. (1) · Andrew Bukowinski (1) · Anthony B El-Khoueiry, MD (1) · Anthony El-Khoueiry, MD (1) · Antoni Ribas, MD, PhD (1) · Brian A Costello (1) · Christine L Hann (1) · Crystal L Mackall (1)
PMID 31401903, PMID 39863139, PMID 23598171, PMID 28032129, PMID 32192573, PMID 33568345, PMID 33881209, PMID 37036756, PMID 37314501, PMID 38270822, PMID 38520670, PMID 39487711, PMID 39998620, PMID 39998852, PMID 40139261, PMID 41118283, PMID 41646361, PMID 41920422
UM1CA097452 (10), UM1CA228823 (5), UM1CA186689 (4), P30CA016672 (3), UM1CA186688 (3), P30CA014089 (2), UM1CA186717 (2), P30CA006516 (1), P30CA015083 (1), P30CA015704 (1), P30CA033572 (1), P30CA072720 (1), P50CA127003 (1), R01CA149627 (1), R01CA195473 (1)